(Q30666435)

26 June 2017

1 reference

1 reference

title

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness (English)

1 reference

cost-effectiveness analysis

26 June 2017

0 references

1 reference

1 reference

Clegg A

1

1 reference

PubMed ID

11336612

26 June 2017

Bryant J

series ordinal

2

1 reference

PubMed ID

11336612

26 June 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Expert Opinion on Pharmacotherapy

26 June 2017

1 reference

26 June 2017

2

1 reference

26 June 2017

4

1 reference

26 June 2017

623-639

1 reference

Drug treatment of multiple sclerosis

26 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

Overview of azathioprine treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

The hazards of scoring the quality of clinical trials for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

The role of MRI in clinical trials of multiple sclerosis: comparison of image processing techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.623

21 January 2018

Identifiers

DOI

10.1517/14656566.2.4.623

1 reference

26 June 2017

1 reference

PubMed ID

11336612